Bulletin
Investor Alert

press release

Feb. 2, 2021, 7:01 a.m. EST

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021

Deciphera Pharmaceuticals, Inc. /zigman2/quotes/203556943/composite DCPH -0.35% today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, February 9, 2021, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 5826559. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations . The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005305/en/

SOURCE: Deciphera Pharmaceuticals, Inc.

Investor Relations:
Jen Robinson
Deciphera Pharmaceuticals, Inc
jrobinson@deciphera.com
781-906-1112 Media:
David Rosen
Argot Partners
David.Rosen@argotpartners.com
212-600-1902

COMTEX_380043190/2456/2021-02-02T07:00:35

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2021

/zigman2/quotes/203556943/composite
US : U.S.: Nasdaq
$ 33.89
-0.12 -0.35%
Volume: 263,256
Oct. 26, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.97 billion
Rev. per Employee
$120,249
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.